Intellia Therapeutics (NTLA), a clinical-stage biotech focused on CRISPR-based gene editing for inherited and autoimmune diseases, sank 42.3% after halting patient dosing in its Phase 3 MAGNITUDE trials following a hospitalisation incident, dragging down peers such as CRISPR Therapeutics and Editas Medicine.